Review article: pathogenesis and treatment of chronic hepatic encephalopathy

Aliment Pharmacol Ther. 1996 Oct;10(5):681-97. doi: 10.1046/j.1365-2036.1996.58200000.x.

Abstract

The various treatment strategies for hepatic encephalopathy are compared in the light of the available body of scientific work on the pathogenesis of the syndrome. Data on animal models of hepatic encephalopathy and in vitro studies on brain slices are discussed. Difficulties in extrapolating the results obtained to the human situation are highlighted, while results of human positron emission tomography and magnetic resonance spectroscopy studies are outlined on the background of the potential weaknesses of these non-invasive techniques.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiology
  • Cerebral Cortex / pathology*
  • Diet
  • Dipeptides / administration & dosage
  • Dipeptides / pharmacology
  • Dipeptides / therapeutic use
  • Disaccharides / administration & dosage
  • Disaccharides / pharmacology
  • Disaccharides / therapeutic use
  • Disease Models, Animal
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / pharmacology
  • Dopamine Agonists / therapeutic use
  • Energy Metabolism
  • GABA Agents / administration & dosage
  • GABA Agents / pharmacology
  • GABA Agents / therapeutic use
  • Hepatic Encephalopathy / drug therapy*
  • Hepatic Encephalopathy / etiology
  • Hepatic Encephalopathy / physiopathology
  • Humans
  • In Vitro Techniques
  • Intestinal Absorption / drug effects
  • Neurotoxins / metabolism
  • Neurotoxins / toxicity
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Tomography, Emission-Computed

Substances

  • Anti-Bacterial Agents
  • Dipeptides
  • Disaccharides
  • Dopamine Agonists
  • GABA Agents
  • Neurotoxins
  • ornithylaspartate